From Gut to Heart: Role of Indole-3-Propionic Acid in HFpEF

HomeCirculation ResearchVol. 134, No. 4From Gut to Heart: Role of Indole-3-Propionic Acid in HFpEF No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextFrom Gut to Heart: Role of Indole-3-Propionic Acid in HFpEF Antonio Vacca and Gabriele G. Schiattarella Antonio VaccaAntonio Vacca https://orcid.org/0000-0003-0051-7723 Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.V., G.G.S.). Clinica Medica, Department of Medicine, University of Udine, Italy (A.V.). and Gabriele G. SchiattarellaGabriele G. Schiattarella Correspondence to: Gabriele G. Schiattarella, MD, PhD, Max Rubner Center for Cardiovascular Metabolic Renal Research, Deutsches Herzzentrum der Charité, Charité -Universitätsmedizin Berlin, Germany. Email E-mail Address: [email protected] https://orcid.org/0000-0002-7582-7171 Max Rubner Center for Cardiovascular Metabolic Renal Research, Deutsches Herzzentrum der Charité, Charité-Universitätsmedizin Berlin, Germany (G.G.S.). German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany (G.G.S.). Translational Approaches in Heart Failure and Cardiometabolic Disease, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany (A.V., G.G.S.). Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy (G.G.S.). Originally published15 Feb 2024https://doi.org/10.1161/CIRCRESAHA.123.323947Circulation Research. 2024;134:390–392This article is a commentary on the followingIndole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection FractionFootnotesFor Sources of Funding and Disclosures, see page 391.The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to: Gabriele G. Schiattarella, MD, PhD, Max Rubner Center for Cardiovascular Metabolic Renal Research, Deutsches Herzzentrum der Charité, Charité -Universitätsmedizin Berlin, Germany. Email gabriele.schiattarella@dhzc-charite.deREFERENCES1. Shah SJ, Borlaug BA, Kitzman DW, McCulloch AD, Blaxall BC, Agarwal R, Chirinos JA, Collin S, Deo RC, Gladwin MT, et al. Research priorities for heart failure with preserved ejection fraction: National Heart, Lung, and Blood Institute working group summary.Circulation. 2020; 141:1001–1026. doi: 10.1161/CIRCULATIONAHA.119.041886LinkGoogle Scholar2. Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review.JAMA. 2023; 329:827–838. doi: 10.1001/jama.2023.2020CrossrefMedlineGoogle Scholar3. Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, Luo X, Jiang N, May HI, Wang ZV, et al. Nitrosative stress drives heart failure with preserved ejection fraction.Nature. 2019; 568:351–356. doi: 10.1038/s41586-019-1100-zCrossrefMedlineGoogle Scholar4. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, Hovingh GK, Kizman DW, Lindegaard ML, Møller DV, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N Engl J Med. 2023; 389:1069–1084. doi: 10.1056/NEJMoa2306963CrossrefMedlineGoogle Scholar5. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, et al. Microbiota in health and diseases.Signal Transduct Target Ther. 2022; 7:135. doi: 10.1038/s41392-022-00974-4CrossrefMedlineGoogle Scholar6. Rahman MM, Islam F, Or-Rashid MH, Mamun AA, Rahaman MS, Islam MM, Farzana A, Sudrathar P, Mitra S, Mimi AA, et al. The gut microbiota (microbiome) in cardiovascular disease and its therapeutic regulation.Front Cell Infect Microbiol. 2022; 12:903570. doi: 10.3389/fcimb.2022.903570CrossrefMedlineGoogle Scholar7. Beale AL, O'Donnell JA, Nakai ME, Nanayakkara S, Vizi D, Carter K, Dean E, Ribeiro RV, Yiallourou S, Carrington MJ, et al. The gut microbiome of heart failure with preserved ejection fraction.J Am Heart Assoc. 2021; 10:e020654. doi: 10.1161/JAHA.120.020654LinkGoogle Scholar8. Wang Y, Yen Chin Koay YC, Pan C, Zhou Z, Mendoza L, Tang WHW, Wilcox J, Li XS, Zagouras A, Marques F, et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction.Circ Res. 2024; 134:371–389. doi: 10.1161/CIRCRESAHA.123.322381LinkGoogle Scholar9. Konopelski P, Mogilnicka I. Biological effects of indole-3-propionic acid, a gut microbiota-derived metabolite, and its precursor tryptophan in mammals' health and disease.IJMS. 2022; 23:1222. doi: 10.3390/ijms23031222CrossrefGoogle Scholar10. Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Adão R, Vasques-Nóvoa F, Freundt JK, Voglhuber J, Pricolo MR, Kasa M, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction.Sci Transl Med. 2021; 13:eabd7064. doi: 10.1126/scitranslmed.abd7064CrossrefMedlineGoogle Scholar11. Tong D, Schiattarella GG, Jiang N, Altamirano F, Szweda PA, Elnwasany A, Lee DI, Yoo H, Kass DA, Szweeda LI, et al. NAD + repletion reverses heart failure with preserved ejection fraction.Circ Res. 2021; 128:1629–1641. doi: 10.1161/CIRCRESAHA.120.317046LinkGoogle Scholar12. Konopelski P, Chabowski D, Aleksandrowicz M, Kozniewska E, Podsadni P, Szczepanska A, Ufnal M. Indole-3-propionic acid, a tryptophan-derived bacterial metabolite, increases blood pressure via cardiac and vascular mechanisms in rats.Am J Physiol Regul Integr Comp Physiol. 2021; 321:R969–R981. doi: 10.1152/ajpregu.00142.2021CrossrefMedlineGoogle Scholar13. Kim CS, Jung S, Hwang GS, Shin DM. Gut microbiota indole-3-propionic acid mediates neuroprotective effect of probiotic consumption in healthy elderly: a randomized, double-blind, placebo-controlled, multicenter trial and in vitro study.Clin Nutr. 2023; 42:1025–1033. doi: 10.1016/j.clnu.2023.04.001CrossrefMedlineGoogle Scholar14. Walker MA, Chen H, Yadav A, Ritterhoff J, Villet O, McMillen T, Wang Y, Purcell H, Djukovic D, Raftey D, et al. Stimulates short-chain dehydrogenase/reductase proteins to alleviate heart failure independent of mitochondrial protein deacetylation.Circulation. 2023; 25:2038–2057. doi: 10.1161/CIRCULATIONAHA.123.066039LinkGoogle Scholar15. Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut microbiota-derived TMAO: a causal factor promoting atherosclerotic cardiovascular disease?Inter J Mol Sci. 2023; 24:1940. doi: 10.3390/ijms24031940CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesIndole-3-Propionic Acid Protects Against Heart Failure With Preserved Ejection FractionYu-Chen Wang, et al. Circulation Research. 2024;134:371-389 February 16, 2024Vol 134, Issue 4 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCRESAHA.123.323947PMID: 38359099 Originally publishedFebruary 15, 2024 KeywordsEditorialsdietgastrointestinal microbiomeheart failureinflammationmetabolismobesitysirtuinsPDF download Advertisement